Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder.
Recourt K, de Boer P, van der Ark P, Benes H, van Gerven JMA, Ceusters M, van Nueten L, Drevets WC, Bhatacharya A, Browning M, Jacobs GE. Recourt K, et al. Among authors: ceusters m. Transl Psychiatry. 2023 Jul 24;13(1):266. doi: 10.1038/s41398-023-02557-5. Transl Psychiatry. 2023. PMID: 37482560 Free PMC article. Clinical Trial.
Pharmacology of a novel central nervous system-penetrant P2X7 antagonist JNJ-42253432.
Lord B, Aluisio L, Shoblock JR, Neff RA, Varlinskaya EI, Ceusters M, Lovenberg TW, Carruthers N, Bonaventure P, Letavic MA, Deak T, Drinkenburg W, Bhattacharya A. Lord B, et al. Among authors: ceusters m. J Pharmacol Exp Ther. 2014 Dec;351(3):628-41. doi: 10.1124/jpet.114.218487. Epub 2014 Sep 30. J Pharmacol Exp Ther. 2014. PMID: 25271258
Efficacy and safety of an adjunctive mGlu2 receptor positive allosteric modulator to a SSRI/SNRI in anxious depression.
Kent JM, Daly E, Kezic I, Lane R, Lim P, De Smedt H, De Boer P, Van Nueten L, Drevets WC, Ceusters M. Kent JM, et al. Among authors: ceusters m. Prog Neuropsychopharmacol Biol Psychiatry. 2016 Jun 3;67:66-73. doi: 10.1016/j.pnpbp.2016.01.009. Epub 2016 Jan 20. Prog Neuropsychopharmacol Biol Psychiatry. 2016. PMID: 26804646 Clinical Trial.
4-Methyl-6,7-dihydro-4H-triazolo[4,5-c]pyridine-Based P2X7 Receptor Antagonists: Optimization of Pharmacokinetic Properties Leading to the Identification of a Clinical Candidate.
Letavic MA, Savall BM, Allison BD, Aluisio L, Andres JI, De Angelis M, Ao H, Beauchamp DA, Bonaventure P, Bryant S, Carruthers NI, Ceusters M, Coe KJ, Dvorak CA, Fraser IC, Gelin CF, Koudriakova T, Liang J, Lord B, Lovenberg TW, Otieno MA, Schoetens F, Swanson DM, Wang Q, Wickenden AD, Bhattacharya A. Letavic MA, et al. Among authors: ceusters m. J Med Chem. 2017 Jun 8;60(11):4559-4572. doi: 10.1021/acs.jmedchem.7b00408. Epub 2017 May 25. J Med Chem. 2017. PMID: 28493698
Clinical pharmacokinetics, pharmacodynamics, safety, and tolerability of JNJ-54175446, a brain permeable P2X7 antagonist, in a randomised single-ascending dose study in healthy participants.
Timmers M, Ravenstijn P, Xi L, Triana-Baltzer G, Furey M, Van Hemelryck S, Biewenga J, Ceusters M, Bhattacharya A, van den Boer M, van Nueten L, de Boer P. Timmers M, et al. Among authors: ceusters m. J Psychopharmacol. 2018 Dec;32(12):1341-1350. doi: 10.1177/0269881118800067. Epub 2018 Sep 27. J Psychopharmacol. 2018. PMID: 30260294 Clinical Trial.
18F-JNJ-64413739, a Novel PET Ligand for the P2X7 Ion Channel: Radiation Dosimetry, Kinetic Modeling, Test-Retest Variability, and Occupancy of the P2X7 Antagonist JNJ-54175446.
Koole M, Schmidt ME, Hijzen A, Ravenstijn P, Vandermeulen C, Van Weehaeghe D, Serdons K, Celen S, Bormans G, Ceusters M, Zhang W, Van Nueten L, Kolb H, de Hoon J, Van Laere K. Koole M, et al. Among authors: ceusters m. J Nucl Med. 2019 May;60(5):683-690. doi: 10.2967/jnumed.118.216747. Epub 2018 Sep 27. J Nucl Med. 2019. PMID: 30262518 Free article.
21 results